Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Mosunetuzumab consolidation for older patients with DLBCL and detectable ctDNA after pola-R-mini-CHP

Phase 2 trial in which people with a radiographic complete response but detectable ctDNA receive mosunetuzumab, and those with undetectable ctDNA are observed. The registry primary outcome is the ctDNA clearance rate. ClinicalTrials.gov lists the study as recruiting.

Danielle Wallace